Shares of Novo Nordisk (NYSE:NVO) slipped about 1% on Wednesday morning after the company issued a cautious outlook, even ...

Novo Nordisk’s weaker results indicate mounting pressure in the weight-loss drug market that it once dominated. The maker of Ozempic and Wegovy is facing tougher competition, slower demand, and ...

According to Reuters, Lilly could offer the lowest dose of its popular weight loss drug Zepbound at $149 a month, and Novo’s ...

Ahead of a reported White House deal meant to lower the cost of obesity drugs like Wegovy, Novo said “intensifying ...

Novo Nordisk lowered its forecasts due to slowing sales of its obesity drugs amid competition from Eli Lilly and generic ...

Pedersen, Maggie Fick and Bhanvi Satija COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on ...

Participants in a multidisciplinary comprehensive obesity care model had clinically meaningful weight loss and high obesity ...

Investors got to hear Novo Nordisk’s side of the Metsera bidding war drama for the first time on Wednesday, as the company ...

Pfizer Inc. is rated a Buy with stable guidance, robust pipeline, strong free cash flows & appealing dividend yield. Learn ...

Less than three months into his tenure, Novo Nordisk’s new CEO has undeniably left his mark on the company, launching a ...

Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to ...

The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.